<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Unalp-Arida A</submitter><pubmed_abstract>&lt;h4>Background and Aims&lt;/h4> Fatty liver disease is a growing public health burden. We estimated prepandemic fatty liver disease prevalence determined by transient elastography-assessed hepatic steatosis and fibrosis, and examined associations with lifestyle and other factors in a United States population sample. &lt;h4>Methods&lt;/h4> Liver stiffness and controlled attenuation parameter (CAP) were assessed on 7923 non-Hispanic white, non-Hispanic black, non-Hispanic Asian, and Hispanic men and women aged 20 years and over in the National Health and Nutrition Examination Survey (NHANES) 2017–March 2020 prepandemic data. &lt;h4>Results&lt;/h4> The prevalence of fatty liver disease (CAP > 300 dB/m) was 28.8% and of fibrosis (liver stiffness > 8 kPa) was 10.4%. Only 7.2% of participants with fatty liver </pubmed_abstract><journal>Digestive diseases and sciences</journal><pagination>1-16</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9521005</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States</pubmed_title><pmcid>PMC9521005</pmcid><pubmed_authors>Ruhl C</pubmed_authors><pubmed_authors>Unalp-Arida A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States</name><description>&lt;h4>Background and Aims&lt;/h4> Fatty liver disease is a growing public health burden. We estimated prepandemic fatty liver disease prevalence determined by transient elastography-assessed hepatic steatosis and fibrosis, and examined associations with lifestyle and other factors in a United States population sample. &lt;h4>Methods&lt;/h4> Liver stiffness and controlled attenuation parameter (CAP) were assessed on 7923 non-Hispanic white, non-Hispanic black, non-Hispanic Asian, and Hispanic men and women aged 20 years and over in the National Health and Nutrition Examination Survey (NHANES) 2017–March 2020 prepandemic data. &lt;h4>Results&lt;/h4> The prevalence of fatty liver disease (CAP > 300 dB/m) was 28.8% and of fibrosis (liver stiffness > 8 kPa) was 10.4%. Only 7.2% of participants with fatty liver </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-05-29T22:02:23.324Z</modification><creation>2025-02-19T01:55:32.502Z</creation></dates><accession>S-EPMC9521005</accession><cross_references/></HashMap>